|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM369234359 |
| 003 |
DE-627 |
| 005 |
20240608002934.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240304s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202311574
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1432.xml
|
| 035 |
|
|
|a (DE-627)NLM369234359
|
| 035 |
|
|
|a (NLM)38433564
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Qi, Shaolong
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Supramolecular Lipid Nanoparticles Based on Host-Guest Recognition
|b A New Generation Delivery System of mRNA Vaccines For Cancer Immunotherapy
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 07.06.2024
|
| 500 |
|
|
|a Date Revised 07.06.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Dendritic cell (DC) maturation is a crucial process for antigen presentation and the initiation of T cell-mediated immune responses. Toll-like receptors play pivotal roles in stimulating DC maturation and promoting antigen presentation. Here, a novel message RNA (mRNA) cancer vaccine is reported that boosts antitumor efficacy by codelivering an mRNA encoding tumor antigen and a TLR7/8 agonist (R848) to DC using supramolecular lipid nanoparticles (SMLNP) as a delivery platform, in which a new ionizable lipid (N2-3L) remarkably enhances the translation efficiency of mRNA and a β-cyclodextrin (β-CD)-modified ionizable lipid (Lip-CD) encapsulates R848. The incorporation of R848 adjuvant into the mRNA vaccine through noncovalent host-guest complexation significantly promotes DC maturation and antigen presentation after vaccination, thus resulting in superior antitumor efficacy in vivo. Moreover, the antitumor efficacy is further boosted synergized with immune checkpoint blockade by potentiating the anticancer capability of cytotoxic T lymphocytes infiltrated in tumor sites. This work indicates that SMLNP shows brilliant potential as next-generation delivery system in the development of mRNA vaccines with high efficacy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a cancer immunotherapy
|
| 650 |
|
4 |
|a host–guest recognition
|
| 650 |
|
4 |
|a lipid nanoparticles
|
| 650 |
|
4 |
|a mRNA vaccine
|
| 650 |
|
4 |
|a supramolecular chemistry
|
| 650 |
|
7 |
|a Cancer Vaccines
|2 NLM
|
| 650 |
|
7 |
|a Lipids
|2 NLM
|
| 650 |
|
7 |
|a Toll-Like Receptor 8
|2 NLM
|
| 650 |
|
7 |
|a Toll-Like Receptor 7
|2 NLM
|
| 650 |
|
7 |
|a Imidazoles
|2 NLM
|
| 650 |
|
7 |
|a Lipid Nanoparticles
|2 NLM
|
| 650 |
|
7 |
|a mRNA Vaccines
|2 NLM
|
| 650 |
|
7 |
|a beta-Cyclodextrins
|2 NLM
|
| 650 |
|
7 |
|a resiquimod
|2 NLM
|
| 650 |
|
7 |
|a V3DMU7PVXF
|2 NLM
|
| 650 |
|
7 |
|a RNA, Messenger
|2 NLM
|
| 650 |
|
7 |
|a betadex
|2 NLM
|
| 650 |
|
7 |
|a JV039JZZ3A
|2 NLM
|
| 650 |
|
7 |
|a Antigens, Neoplasm
|2 NLM
|
| 650 |
|
7 |
|a TLR8 protein, mouse
|2 NLM
|
| 650 |
|
7 |
|a Liposomes
|2 NLM
|
| 700 |
1 |
|
|a Zhang, Xueyan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Xinyang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jin, Lulu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Kai
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Yangfan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Feng, Yunxuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lei, Jiaqi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mao, Zhengwei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yu, Guocan
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 23 vom: 15. Juni, Seite e2311574
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:23
|g day:15
|g month:06
|g pages:e2311574
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202311574
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 23
|b 15
|c 06
|h e2311574
|